Popular Articles

Brazil's Scientific Research On The Rise, Thomson Reuters Study Finds
Thomson Reuters today announced the results of a study documenting Brazil"s steady rise during the last two decades in both the volume and impact of its scientific work. According to Science Watch, these findings underscore Brazil"s standing among the emergent "BRIC" nations. BRIC -- an acronym for Brazil, Russia, India and China -- are the countries possessing the res and economic potential to capture a significant share of the world"s future economic growth.
generic viagra online
Indiana University Simon Cancer Center's Tissue Bank Collecting Samples Aug. 8
Although Hispanic women tend to develop breast cancer less than Caucasian women, it is usually more aggressive and advanced when it does develop.
News of the day
Chinese Government Reports Abortion Statistics
Chinese state media on Thursday reported that women in the country have about 13 million abortions annually, the AP/Houston Chronicle reports. According to the China Daily newspaper, the actual number likely is much higher because the 13 million includes abortions performed in hospitals but not unreported procedures performed in rural clinics. Most of the abortions were among single young women who experts say know little about contraception. The paper also said that about 10 million pills for medical abortion are sold annually in the country. China imposed strict population controls in the 1970s that prohibit most couples from having more than one child. For married women, sterilization and the use of intrauterine devices are widely promoted and subsidized. However, Chinese policies typically do not address the needs of unmarried women, even as national attitudes have become more accepting of sex outside of marriage, the AP/Chronicle reports. According to the newspaper, about 62% of the abortions were among unmarried women ages 20 to 29. The Chinese report called the number of abortions "an unfortunate situation" but did not indicate whether the procedures are increasing or decreasing from year to year. National Population and Family Planning Commission official Wu Shangchun is quoted in the report as saying that almost half of the women seeking abortion had used no form of contraception. Wu also said that reducing abortions is a national challenge that requires significant effort. Peking University professor Li Ying said that sex education in China must be improved at the university level and that Chinese parents must do more to teach children about sex (AP/Houston Chronicle, 7/30).
Health Insurance

MAP Pharmaceuticals Announces Termination Of Pediatric Asthma Collaboration

MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) announced that it has received a notice of termination of the license agreement with AstraZeneca related to the company"s Unit Dose Budesonide (UDB) product candidate. The termination was received on July 8, 2009, effective immediately. All rights licensed to AstraZeneca in the agreement now revert to the company. MAP Pharmaceuticals plans to suspend development of UDB, which did not meet primary endpoints in a Phase 3 trial in children 12-months to eight years of age with mild asthma. "Physicians and parents continue to express a need for improved therapies for pediatric asthma that offer faster nebulization times, lower doses of steroid exposure, improved treatment compliance and reduced side effects when compared to currently available therapies. MAP Pharmaceuticals is considering options for its pediatric asthma program moving forward, including the development of a next generation therapy with budesonide," said Timothy S. Nelson, president and chief executive officer of MAP Pharmaceuticals. "Separately, MAP Pharmaceuticals remains focused on developing our LEVADEX(TM) migraine therapy, which recently achieved all four primary endpoints in a Phase 3 clinical trial, with the goal of bringing this differentiated treatment to the many patients who suffer from the debilitating effects of migraine." MAP Pharmaceuticals will provide updated financial guidance for 2009 in its second quarter results release. MAP Pharmaceuticals finished the first quarter of 2009 with cash and cash equivalents of $67.7 million and $4.7 million in accounts receivables. About MAP Pharmaceuticals MAP Pharmaceuticals is dedicated to developing and commercializing new therapies for patients suffering from conditions that are not adequately treated by currently available medicines. LEVADEX inhaled therapy is being developed for the potential treatment of migraine and has completed a successful Phase 3 trial. In addition, MAP Pharmaceuticals generates new pipeline opportunities by applying its proprietary drug particle and inhalation technologies to enhance the therapeutic benefits of proven drugs, while minimizing risk by capitalizing on their known safety, efficacy and commercialization history. LEVADEX and Tempo are trademarks of MAP Pharmaceuticals, Inc. Forward-Looking Statements In addition to statements of historical facts or statements of current conditions, this press release contains forward-looking statements, including with respect to the company"s development programs, including MAP Pharmaceuticals" LEVADEX product candidate. Actual results may differ materially from current expectations based on risks and uncertainties affecting the company"s business, including, without limitation, risks and uncertainties relating to the development of drug candidates, the conduct and completion of clinical trials, risks related to the failure to achieve favorable clinical outcomes or to have the company"s LEVADEX product candidate approved for commercial use. The reader is cautioned not to unduly rely on the forward-looking statements contained in this press release. MAP Pharmaceuticals expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law. MAP Pharmaceuticals, Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):